What is known in pre-, peri-, and post-procedural anticoagulation in micro-axial flow pump protected percutaneous coronary intervention?
Authors:
Open Access
- 8 December 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 24 (Supplement) , J17-J24
Abstract
Interest in the use of percutaneous left ventricular assist devices (p-LVADs) for patients undergoing high-risk percutaneous coronary intervention (PCI) is growing rapidly. The Impella™ (Abiomed Inc.) is a catheter-based continuous micro-axial flow pump that preserves haemodynamic support during high-risk PCI. Anticoagulation is required to counteract the activation of the coagulation system by the patient’s procoagulant state and the foreign-body surface of the pump. Excessive anticoagulation and the effect of dual antiplatelet therapy (DAPT) increase the risk of bleeding. Inadequate anticoagulation leads to thrombus formation and device dysfunction. The precarious balance between bleeding and thrombosis in patients with p-LVAD support is often the primary reason that patients’ outcomes are jeopardized. In this chapter, we will discuss anticoagulation strategies and anticoagulant management in the setting of protected PCI. This includes anticoagulant therapy with unfractionated heparin, direct thrombin inhibitors, DAPT, purge blockage prevention by bicarbonate-based purge solution, and monitoring by activated clotting time, partial thromboplastin time, as well as anti-factor Xa levels. Here, we provide a standardized approach to the management of peri-interventional anticoagulation in patients undergoing protected PCI.Keywords
Funding Information
- Abiomed Europe GmbH to cover publication costs of each manuscript
- Abiomed GmbH
This publication has 43 references indexed in Scilit:
- Impella ventricular support in clinical practice: Collaborative viewpoint from a European expert user groupInternational Journal of Cardiology, 2015
- Ticagrelor Crushed Tablets Administration in STEMI PatientsJACC, 2015
- Effective Anticoagulation for a Percutaneous Ventricular Assist Device Using a Heparin-Based Purge SolutionAnnals of Pharmacotherapy, 2013
- Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary SyndromesNew England Journal of Medicine, 2013
- Discordant aPTT and Anti-Xa Values and Outcomes in Hospitalized Patients Treated with Intravenous Unfractionated HeparinAnnals of Pharmacotherapy, 2013
- A Prospective, Randomized Clinical Trial of Hemodynamic Support With Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing High-Risk Percutaneous Coronary InterventionCirculation, 2012
- Extended use of a percutaneous left-ventricular assist device without a heparin-based purge solutionAmerican Journal of Health-System Pharmacy, 2010
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- A Randomized Clinical Trial to Evaluate the Safety and Efficacy of a Percutaneous Left Ventricular Assist Device Versus Intra-Aortic Balloon Pumping for Treatment of Cardiogenic Shock Caused by Myocardial InfarctionJACC, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007